HALAVEN Side Effects by Likelihood and Severity
low amount of calcium in the blood low amount of potassium in the blood a significant drop in a certain type of white blood cell called a neutrophil ...
read more

Does HALAVEN Interact with other Medications?
These medications are not usually taken together. Consult your healthcare professional (e.g., doctor or pharmacist) for more in formation. Sorry, we have no data ...
read more
Cancer-fighting sponges
Halaven, a drug derived from a sea sponge compound came on the market in Nov. 2010, and has improved survival among women who have metastatic breast cancer. NBC’s Anne Thompson reports.
read more
FDA Approves Trastuzumab Deruxtecan in HER2-Low Metastatic Breast Cancer
Patients administered chemotherapy received capecitabine (Xeloda; 20.1%), eribulin (Halaven; 51.1%), gemcitabine (10.3%), paclitaxel (8.2%), or nab-paclitaxel (Abraxane; 10.3%). Of those enrolled in ...
read more

Knight Therapeutics Reports Second Quarter 2022 Results
Knight Therapeutics Inc. (TSX: GUD) (“Knight” or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, ...
read more
FY2022 EPS Estimates for Knight Therapeutics Inc. Lowered by National Bank Financial (TSE:GUD)
National Bank Financial lowered their FY2022 earnings estimates for Knight Therapeutics in a report issued on Monday, August 8th. National Bank Financial analyst E. Leno now forecasts that the company ...
read more
Stocks in play: Knight Therapeutics Inc
Announced today that its Colombian affiliate, Biotoscana Farma S.A. has obtained INVIMA approval for Halaven® (eribulin) injection. Halaven® (eribulin) injection is indicated for the treatment ...
read more
Connective Tissue Oncology Society
PFS rate of 69% at 12 weeks in liposarcoma patients with eribulin and pembrolizumab A combination of eribulin (Halaven) and pembrolizumab (Keytruda) offered promising results in patients with ...
read more
Eisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call Transcript
Q1 2023 Earnings Conference Call August 5, 2022 3:00 AM ET Company Participants Tatsuyuki Yasuno - SVP, CFO & Chief IR Officer Ivan Cheung - SVP, ...
read more
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2021
HALAVEN, a halichondrin class microtubule dynamics inhibitor, "eribulin"). At this congress, differences in outcomes by histology and prior therapy in the pivotal Phase 3 Study 309/KEYNOTE-775 ...
read more
Related Blogs:
Eribulin Halaven Financial Company Patients